Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma | BMC Cancer | Full Text

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma | BMC Cancer | Full Text

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearran...

Authors:Travers Ching, Megan E. Duncan, Tera Newman-Eerkes, Mollie M. E. McWhorter, Jeffrey M. Tracy, Michelle S. Steen, Ryan P. Brown, Srivatsa Venkatasubbarao, Nicholas K. Akers, Marissa Vignali, Martin E. Moorhead, Drew Watson, Ryan O. Emerson, Tobias P. Mann, B. Melina Cimler, Pamela L. Swatkowski…

Citation:BMC Cancer 2020 20:612

Content type:Research article

 

Published on: 30 June 2020

• ViewFull Text
 
• ViewPDF